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Abstract
Mesenchymal stem cells (MSCs) have been used experimentally and clinically in the treatment of  a wide variety 
of  pathologies. MSCs can be safely transplanted in autologous and allogeneic ways as they are non-immunogen-
ic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases 
like scleroderma and fistulizing colitis like in Crohn’s disease (CD). The immunomodulatory properties of  MSCs 
have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evi-
dence suggests that these properties may also be exploited in the treatment of  several other conditions.
The currently available experimental and clinical data indicate that, similar to previously obtained data in the set-
ting of  HSCT, MSC treatment for IBD is feasible and safe. Aim of  this review is to analyze the pathophysiologi-
cal insights for the use of  MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about 
the efficacy and safety of  stem cell therapy in such disorders.
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Introduction
Mesenchymal stem cells (MSCs) have been used ex-
perimentally and clinically in the treatment of  a wide 
variety of  pathologies. It is now clear that a number 
of  different mechanisms contribute to the therapeutic 
effects exerted by these cells. The ability of  MSCs to 
interact with and modulate the functions of  a wide va-
riety of  immune cells has been recognized as one such 
mechanism (1).
MSCs can be safely transplanted in autologous and al-
logeneic ways as they are non-immunogenic, and con-
sequently represent a therapeutic option for refractory 
connective tissue diseases, fibrosing diseases like scle-
roderma and fistulizing colitis like in Crohn’s disease. 
Actually, there are more than 200 registered clinical 
trial sites for evaluating MSC therapy, and 22 are on 
autoimmune diseases (2).
When entering the clinical arena, a few potential risks 
of  MSC therapy have to be taken into account: (i) im-
munogenicity of  the cells, (ii) biosafety of  medium 
components, (iii) risk of  ectopic tissue formation, and 
(iv) potential in vitro transformation of  the cells dur-
ing expansion (3)
Aim of  this review is to analyze the pathophysiological 
insights for the use of  MSCs in inflammatory bowel 
diseases, and to summarize the clinical evidences about 
the efficacy and safety of  stem cell therapy in such dis-
orders.
Immunomodulatory Properties of  Mesen-
chimal Stem Cells
MSCs are easily obtained and can be maintained and 
expanded in culture for later use. In recent years, much 
enthusiasm has been generated concerning the use of  
these previously harvested and expanded cells as a ther-
apeutic modality for a wide range of  conditions. MSCs, 
for example, have been seeded on biologic mesh in an 
attempt to generate new bone or cartilage and infused 
directly into the myocardium in an attempt to improve 
myocardial healing and function following myocardial 
infarction (4-8). Interestingly, despite the wealth of  in-
formation that has been learned about MSCs follow-
ing ex vivo  expansion and subsequent transplantation, 
their true in vivo  function remains somewhat poorly 
understood.
Although readily obtained from such sources as bone 
marrow and adipose tissue, these cells comprise only 
minute proportions of  the total population of  cells 
in these tissues and their numbers appear to decline 
substantially with age (9-10). Because of  their relative 
scarcity, determining what specific role these cells play 
under homeostatic and/or pathologic conditions has 
been difficult.
MSC act as potent modulators of  immune responses 
by their (in vitro) ability to suppress T cell proliferation 
(11). Immune modulation requires their previous acti-
vation by immune cells through the proinflammatory 
cytokines interferon gamma (IFN-γ), tumour necrosis 
factor α (TNF-α) or interleukin- 1β (IL-1β) (12). More-
over, indoleamine-2,3-dioxygenase, heme oxidase as 
well as human leukocyte antigen G5 (HLA-G5) have 
been involved in MSC-mediated immune modulation. 
A distinct subpopulation of  MSC, characterized by 
the expression of  CXCL12 and vascular cell adhesion 
molecule-1, might provide a survival niche for memory 
plasma cells (13). Besides immune modulation, MSC 
exhibit healing capacities, improve angiogenesis and 
prevent fibrosis (14). Prostaglandin E2 (PGE2) is in-
volved in the immunosuppressive activity of  MSCs. 
PGE2 acts as a powerful immune suppressant repre-
senting inhibiting T cell mitogenesis and interleukin-2 
production, and is a cofactor for the induction of  T 
helper (Th) type 2 lymphocyte activity. Production of  
PGE2 by MSC is enhanced following TNF-α or IFN-γ 
stimulation. The use of  specific inhibitors resulted in 
restoration of  T lymphocyte proliferation (15). MSC-
derived PGE2 was shown to act on macrophages by 
stimulating the production of  interleukin-10 (IL-10) 
and on monocytes by blocking their differentiation to-
ward dendritic cells (DCs) (16,17).
The interleukin IL-6, a major MSC-secreted factor, 
has been reported to be involved in the inhibition of  
monocyte differentiation toward DCs , decreasing 
their stimulation ability on T cells (18,19). In parallel, 
the secretion of  IL-6 by MSC was reported to delay 
apoptosis of  lymphocytes and neutrophils (20,21). 
HLA-G5 by MSC was recently shown to suppress T 
cell proliferation, as well as NK cell cytotoxicity and 
T cell cytotoxicity, and to promote the generation of  
regulatory T (TREG) cells. Cell contact between MSC 
and activated T cells induced IL-10 production, which 
was essential to stimulate the release of  soluble HLA-
G5 (22,23).
Both in vitro and in vivo, MSC promote the generation 
of  CD4+CD25+ or CD8+ TREG cells with function-
al properties (24). In vivo data, however, are contra-
dictory (25,26). Recent studies suggest that MSC may 
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induce a cytokine profile shift in the Th1/Th2 balance 
toward the antiinflammatory phenotype Th2 that is 
accompanied by an increase of  T regulatory lympho-
cytes and in consequence an increase of  IL10 (27,28). 
MSC inhibit the proliferation of  B lymphocytes that 
are activated with antiimmunoglobulin antibodies, sol-
uble CD40 ligand or cytokines (29). The use of  human 
adipose tissue-derived MSC led to decreased antigen-
specific Th1/Th17 cell expansion, enhanced secretion 
of  IL-10 and generation of  CD4+CD25+FoxP3+ 
TREG cells with the capacity to suppress selfreactive 
T effector responses in a xenogeneic collageninduced 
arthritis model (30)
Mechanism of  Msc Action
The study of  human MSCs derived from subcutane-
ous adipose tissue (hASCs) in the 5% dextran sulfate 
sodium (DSS) mouse model has shown that hASCs 
inhibit T-cell activation with the superantigen staphy-
lococcal enterotoxin E (SEB), as measured by cytokine 
secretion and T-cell proliferation. The inhibitory effect 
was partially reversed when peripheral blood mono-
nuclear cells (PBMCs) and hASCs were separated by a 
semipermeable Transwell membrane suggesting partial 
cell–cell contact dependence (31). Moreover, the co-
culture of  allogeneic PBMCs and hASCs in the same 
chamber of  the Transwell system fully restored their 
inhibitory activity on SEB-activated PBMCs situated 
in the other chamber, suggesting that PBMC– hASC 
contact induces the secretion of  an immunosuppres-
sive factor(s) for T cells. IL-10 production increased in 
a cell– cell contact-dependent manner in cocultures of  
hASC with PBMCs or monocytes but not with T cells. 
IL-10 blockade partially reversed the inhibitory activity 
of  hASC on T cells.
Modifications in MSCs decrease or enhance their im-
munomodulatory effects (32-34). Duijvestein et al. re-
cently showed that IFN-γ-stimulated MSCs (IMSCs), 
but not nonstimulated MSCs, showed a significantly 
attenuated DSS-induced colitis and trinitro-benzene 
sulfunate–induced colitis. Human MSCs significantly 
inhibited PBMC proliferation at lower PBMC:IMSC 
ratios compared with untreated MSCs, indicating that 
IMSCs have higher immunomodulatory capacities. 
Treatment with mouse IMSCs resulted in significant-
ly lower serum amyloid A levels, confirming the de-
creased inflammatory responses observed in these ani-
mals. IMSC migration to the intestine was significantly 
increased during colitis induction, whereas MSC dis-
tribution was unaffected, suggesting that IMSCs gain 
homing potential to sites of  inflammation (32). Ko et 
al. recently showed that when cells were coated with 
antiaddressin antibody and injected into C57BL6 mice 
with DSS-induced colitis, the mice showed dramatically 
improved survival rates, higher IBD therapeutic scores, 
and significantly improved body weight gain compared 
with mice injected with MSC-only, isotype Ab, free Ab 
plus MSCs, or vehicle-only controls (33). hASC-treated 
colitic mice had significantly higher numbers of  T reg-
ulatory cells (Tregs) in mesenteric lymph nodes than 
untreated colitic mice, and they persisted for a long pe-
riod of  time. In vivo depletion of  IL-10 or CD25+ T 
cells partially reversed the beneficial action of  hASCs 
on colitis, demonstrating involvement of  a therapeutic 
effect. When cells were coated with antibody against 
vascular cell adhesion molecule-1 (Ab VCAM-1-MSC), 
mice exhibited a percentage of  Tregs nearly five times 
greater than with PBS-only-injected mice (analysis of  
variance, P < 0.0001), whereas MSC-onlyinjected mice 
showed nearly a tripling of  the Treg percentage com-
pared with PBS-injected mice (P < 0.05) (34).
Colons of  hASC-treated mice contained reduced lev-
els of  inflammatory cytokines (TNF-α, IFN-γ, IL-6, 
IL-1β, and IL-12), chemokines (RANTES), and mac-
rophage inflammatory protein-2 and increased levels 
of  the anti-inflammatory/ regulatory cytokine IL-10 
in comparison with untreated DSS colitic mice. This 
effect was not just a consequence of  a diminished in-
flammatory infiltration in the mucosa because mon-
onuclear cells isolated from the lamina propria of  
hASCtreated mice produced less TNF-α, IL-12, and 
IFN-γ on ex vivo culture, suggesting that hASC deac-
tivated the colonic inflammatory response (31). Both 
syngeneic and allogeneic murine ASCs were as effi-
cient as hASCs in ameliorating the colitis suggesting 
that the immunosuppressive action of  ASCs is non– 
major histocompatibility complex (MHC)–restricted 
and that the infused ASCs are immune-tolerated by the 
host, which is convenient for future clinical application 
of  these cells in CD (31). 
Msc Therapy
Systemic Infusion of  Human MSCs
In the first human trial of  systemic MSCs in CD, Onken 
et al. , from Duke University, treated 10 patients who 
had failed previous treatment with steroids and immu-
nosuppressants and had active disease; patients were 
randomized to receive either low- (2 million cells/kg) 
or high-dose (8 million cells/kg) i.v., allogenic, third-
party, healthy, human bone marrow– derived MSCs as 
i.v. Infusions in two doses 7 d apart. All nine evaluable 
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patients had a decrease in CDAI score by day 28. Mean 
CDAI scores decreased significantly from baseline to 
day 28 (341 vs. 236, P  = 0.004, Wilcoxon signed rank). 
The primary end point was clinical response defined as 
a ≥100-point reduction in CDAI. This response was 
achieved in 3 patients (33%) by day 14, 2 of  whom met 
the end point within 7 d of  the first infusion. All clini-
cal responders had previously failed infliximab therapy. 
Mean IBD quotient scores increased significantly from 
baseline to day 28 (113 vs. 146, P  = 0.008, Wilcoxon 
signed rank). IBD quotient scores increased to ≥170 in 
22% of  patients by day 14 and 38% by day 28. There 
appeared to be an association between mean change 
in IBD quotient and clinical response at day 28 (P  = 
0.07, Wilcoxon rank sum). Although not statistically 
significant, the mean reduction in the CDAI score at 
day 28 was greater in the high-dose than in the  low-
dose group (−137 vs. −65, P  = 0.39, Wilcoxon rank 
sum). All infusions were well tolerated, and there were 
no treatmentrelated serious adverse events  (35). 
Another phase I study of  autologous bone marrow– 
derived MSCs for luminal refractory CD was published 
in the Netherlands. Enough MSCs were expanded in 
9 of  10 patients to administer two doses of  1–2 Å~ 
106  cells/kg body weight, intravenously, 7 d apart. All 
patients had previously failed corticosteroids, at least 
two anti-TNF drugs, and 9 of  10 patients also had 
failed two immunosuppressants (thiopurine and meth-
otrexate). In this study, no clear signal of  efficacy was 
observed; remission was not achieved in any patient, 
and 3 patients had a reduction of  at least 70 points 
in CDAI, but the disease worsened significantly in 4 
patients requiring surgery (three cases) or rescue medi-
cation (one case) within 14 wk after cell treatment. 
Endoscopy improved in two cases, but no significant 
changes in C-reactive protein levels were seen (36). 
The currently ongoing largest, randomized, placebo-
controlled, double-blind phase III study of  prochymal 
(allogenic marrow–derived MSCs) in CD was initi-
ated in 2007 by Osiris (http://clinicaltrials.gov/ct2/
show/NCT00294112). The study plan is to enroll 270 
patients with active CD (CDAI 250–450) who have 
a history of  treatment failure with or intolerance to 
steroids, immunosuppressants, and biologics. Patients 
are randomized to receive four infusions over 2 wk of  
either 600 million cells (low dose: two infusions of  200 
Å~ 106  hMSCs in week 1, then two infusions of  100 
Å~ 106  hMSCs in week 2), 1,200 million cells (high 
dose: two infusions of  400 Å~ 106  hMSCs in week 
1, then two infusions of  200 Å~ 106  hMSCs in week 
2) or placebo. The primary end point of  the study is 
remission at day 28 with secondary end points being 
clinical response, improved quality of  life (increased 
IBD quotient score), and decreased number of  drain-
ing fistulae.
Local Injection of  MSCs in CD
The first trial of  cell therapy using autologous MSCs 
(ASCs) obtained from a lipoaspirate for local treat-
ment of  fistulae for CD in 5 patients was published 
in 2005 (37). The same group published a phase II, 
multicenter, randomized controlled trial describing the 
effectiveness and safety of  ASCs in the treatment of  
complex perianal fistulas in 2009. Patients with com-
plex perianal fistulas (cryptoglandular origin, n = 35; 
associated with CD, n = 14) were randomly assigned 
to intralesional treatment with fibrin glue or fibrin glue 
plus 20 million ASCs.
Fistula healing and quality of  life (SF-12 questionnaire) 
were evaluated at 8 wk and 1 y. If  healing was not seen 
at 8 wk, a second dose of  fibrin glue or fibrin glue 
plus 40 million ASCs was administered. Fistula healing 
was observed in 17 (71%) of  24 patients who received 
ASCs in addition to fibrin glue, compared with 4 (16%) 
of  25 patients who received fibrin glue alone (relative 
risk for healing, 4.43; confidence interval, 1.74–11.27; P 
< 0.001). The proportion of  patients with healing was 
similar in CD and non-CD subgroups. ASCs were also 
more effective than fibrin glue alone in patients with a 
suprasphincteric fistulous tract (P = 0.001). Quality-of-
life scores were higher in patients who received ASCs 
than in those who received fibrin glue alone. At 1-y 
follow-up, the recurrence rate in patients treated with 
ASCs was 17.6%. Both treatments were well tolerated 
(38). In a second study, published recently, a local injec-
tion of  autologous marrow–derived MSCs was given 
to nine patients with perianal and one patient with en-
terocutaneous fistulas. Injections of  a median of  20 
Å~ 106 cells (range 15–30) were given every 4 wk until 
a response was obtained or no more cells were avail-
able. Complete fistula closure sustained for 1 y was ob-
tained in 7 patients and a response (reduction of  at least 
50% of  fistula tracts) in 3. Furthermore, all 9 patients 
with perianal fistulas had active disease in the rectum at 
baseline, and healing of  rectal lesions was observed in 
the 7 patients who underwent endoscopy at month 12 
of  follow-up. Thus, the latter study suggests a consid-
erable therapeutic benefit of  local injection of  MSCs 
in fistulizing lesions (39). At this stage, reasons for the 
apparent discrepancies between efficacy of  local injec-
tion of  MSCs for treatment of  fistulas compared with 
systemic administration for treatment of  luminal CD 
are not completely clear. MSCs have been reported to 
Emanuele Sinagra, International Journal of Stem Cell Research and Transplantation 2013, 1:301 5
home to sites of  injury and disease following i.v. in-
fusion and contribute to the repair process. The ex-
pression of  adhesion molecules and chemokine recep-
tors on MSCs may be responsible for their ability to 
migrate selectively to sites of  inflammation through a 
ICAM1- and VCAM1-dependent interaction with en-
dothelial cells (40). In an experimental model of  coli-
tis, systemically injected human adipose tissue–derived 
MSCs were detected in the mesenteric lymph nodes 
and spleen of  the recipient colitic mice 1–3 d post in-
jection (31). Interestingly, labeled MSCs were recruited 
by the inflamed colon but not by the noninflamed in-
testine. However, the proportion of  cells recruited to 
inflamed or damaged organs and the survival of  cells 
at sites of  inflammatory lesions remain to be clarified, 
a necessary prerequisite for optimizing a potential sys-
temic treatment. In studies showing efficacy of  local 
injections, of  human autologous MSCs, 30–60 Å~ 106 
are injected in a single fistulous tract, and these injec-
tions are generally repeated (38,39). In a study using 
systemic injection for treatment of  luminal disease, a 
higher number of  100–400 Å~ 106 allogenic or au-
tologous MSCs were injected (32). Considering the ex-
tension of  the inflamed intestine, and the fact that only 
a portion of  the MSCs will reach the inflamed organ, 
the cell density at sites of  luminal inflammation would 
be considerably lower than that achieved in fistula 
tracts by local injection. To circumvent this, Ghosh et 
al., from the United Kingdom, injected haploidentical 
MSCs after catheterization of  the mesenteric artery via 
the femoral route into a 35-y-old patient with severe 
refractory fistulizing CD failing all conventional thera-
pies, biological therapies, and surgical defunctioning 
ileostomy. The patient received 105/kg MSCs, and 4 
wk later a second dose of  106/kg (41). The pretreat-
ment CDAI was 384; it dropped to 258 2 weeks after 
the first infusion and remained as such at the time of  
the second infusion administered after 4 wk. Magnetic 
resonance imaging of  the abdomen/pelvis post–MSC 
treatment showed slight changes in the transphincteric 
fistulae on the right and an unchanged horseshoe in-
tersphincteric extension on the left side. There was no 
adverse effect. All the above studies point  to a differ-
ence in cell density achieved at inflammatory sites, with 
systemic and local injections. Ongoing trials are testing 
fourfold higher systemic doses (42).
Safety Issues
When considering the use of  ex vivo expanded MSCs 
for clinical application, several potential risks should 
be considered: (i) the immunogenicity of  the cells, (ii) 
the biosafety of  medium components, (iii) the risk of  
ectopic tissue formation, and (iv) the potential in vitro 
transformation of  the cells during expansion (3)
Immunogenicity
Concerning the immunogenicity of  MSCs, it has been 
demonstrated that MSCs are not intrinsically immuno-
privileged. Infusion of  allogeneic MSCs into immu-
nocompetent and major histocompatibility complex 
(MHC)-mismatched mice may induce an immune re-
sponse, resulting in their rejection (43).  On the con-
trary, the infusion of  syngeneic host–derived MSCs 
resulted, in the same mouse model, in enhanced en-
graftment of  allogeneic stem cells (43). Moreover, it 
has been demonstrated that IL-2–activated autologous 
and allogeneic natural killer (NK) cells are capable of  
effectively lysing MSCs in vitro (44) . Although MSCs 
express normal levels ofMHC class I, which should 
protect against NK-mediated killing, they display li-
gands that are recognized by activating NK receptors 
that, in turn, trigger NK alloreactivity (44). The major-
ity of  the clinical reports on MSC therapeutic applica-
tion have suggested low immunogenicity of  MSCs in 
humans.  However, when gene-markedMSCs were em-
ployed to treat children with osteogenesis imperfecta, 
the gene-marked cells were not detected in the treated 
patients, indicating their potential recognition and re-
jection by the host immune system (45).
On the basis of  these experimental and clinical find-
ings, some fundamental issues should be taken into 
consideration when determining the clinical applica-
tion of  MSCs, including whether autologous or alloge-
neic MSCs should be employed, the state of  immune 
competence of  the patient at time of  infusion, and the 
number of  infusions needed to treat the patient.
The Safety of  The Culture Medium
Although current standard conditions for ex vivo  ex-
pansion of  MSCs are based on the presence of  fetal 
calf  serum (FCS), the use of  bovine proteins might be 
associated with the risk of  transmission of  zoonoses 
and potential immune reactions in the host, resulting 
in rejection of  the cells especially after repeated treat-
ments (46,47). For these reasons, various animal-free 
additives have been considered for clinical-grade ex-
pansion ofMSCs: autologous and allogeneic human-
serum (48), cytokines and growth factors (49),  and 
platelet lysate (PL)/platelet rich plasma (PRP) (50). 
In particular, PL/PRP has been proposed as a suit-
able and efficacious candidate substitute for FCS in 
the near future (50-52).  Several research groups have 
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demonstrated that the growth factors contained in PL/
PRP are able to promote MSC expansion, and that a 
concentration of  PL/PRP of  5% is sufficient to guar-
antee the optimal growth of  MSCs while substantially 
preserving their biological and functional properties, 
including those relating to modulation of  immune re-
sponses (50-52).
However, clinical trials conducted so far have mainly 
employed FCS-expanded cells, and available data in 
vivo  on PL/PRP-cultured MSCs are still scarce. There-
fore, these latter cells need to be extensively tested in 
vivo  before being considered as a safe and effective 
substitute for MSCs generated in the presence of  FCS-
based media.
Ectopic Tissue Formation
One of  the potential risks of  MSC treatment involves 
the formation of  mesenchymal tissues at ectopic sites. 
In a rat myocardial infarction model, it has been re-
ported that MSCs may form bone following local in-
jection into the myocardium (53).  Similarly, formation 
of  adipose tissue in kidneys has been observed in a 
rat model of  experimental glomerulonephritis (54). 
Moreover, it has been recently reported in amurine 
model of  GvHD that local implantation of  MSCs re-
sulted in ectopic bone formation in syngeneic recipi-
ents, whereas it lead to transplant rejection in alloge-
neic mice (55).  These studies underline the potential 
danger of  ectopic tissue formation in patients treated 
with MSCs for myocardial infarction and other diseas-
es; however, in clinical trials so far, no ectopic tissue or 
tumor formation in vivo  has been observed. Few stud-
ies have attempted to specifically address this concern, 
and factors governing the postinfusion fate ofMSCs 
and the influence of  the local environment on MSC 
behavior are still largely unknown and need further in-
vestigation. Therefore, a strict and long-term follow-
up of  patients treated with MSCs is recommended to 
monitor the potential formation of  mesenchymal tis-
sues at ectopic sites.
Malignant Transformation
It has been shown by a few groups that longterm ma-
nipulation in vitro of  both adipose tissue (AT) and bone 
marrow (BM)–derived MSCs may alter their functional 
and biological properties, leading to the accumulation 
of  genetic alterations and malignant transformation 
(56-58). By contrast, other researchers have suggested 
that human MSCs of  various tissue origin can be cul-
tured in vitro long term without losing their usual phe-
notypical/functional characteristics and without devel-
oping chromosomal aberrations (59-61). In particular, 
genetic studies performed through  both conventional 
karyotyping and molecular techniques, such as array-
comparative genomic hybridization (array-CGH), have 
been employed to document the absence of  chromo-
somal abnormalities in cultured MSCs (59-61)
Telomere length and telomerase activity analyses, to-
gether with the study of  several proteins and genes in-
volved in the regulation of   cell cycle, senescence, and 
tumorigenesis have been also tested, confirming the 
absence of  transformation (59,61) Moreover, French 
researchers have demonstrated that the occasional 
presence of  aneuploidy in some MSC preparations 
may be related to the occurrence of  senescence, but 
not to the development of  transformation (61).
More importantly, the reports on MSC malignant trans-
formation have been recently retracted because it was 
found that the tumor cells in MSC cultures were unre-
lated to the original MSCs; rather, they derived from 
contaminating tumor cell lines (62,63). Together, these 
data indicate that malignant transformation in ex vivo 
expanded humanMSCs is likely to be an extremelyun-
commonevent, estimated to be in the frequency of< 
10−9 (64). As a general recommendation, phenotypic, 
functional and genetic assays, although known to have 
limited sensitivity, should be routinely performed on 
MSCs before in vivo  use; in particular, a genetic char-
acterization of  MSCs through conventional/molecular 
karyotyping may be consideredbefore release of  MSCs 
for clinical application, in particular for patient-derived 
MSCs.
Conclusions
Adult-tissue stem cells have a property that makes 
them attractive to research¬ers in the emerging field 
of  regenerative . In particular, the immunomodulatory 
properties of  MSCs have already shown promise when 
used as therapy for otherwise medically refractory CD. 
Accumulating evidence suggests that these properties 
may also be exploited in the treatment of  several other 
conditions.
The currently available experimental and clinical data 
indicate that, similar to previously obtained data in the 
setting of  HSCT, MSC treatment for IBD is feasible 
and safe. Neither early toxicity nor later side effects 
have been registered in treated patients, although a 
longer follow-up is necessary to drawdefinitive conclu-
sions on potential long-term adverse events.
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Ongoing efforts focused on evaluating in vivo  effec-
tiveness, shortcomings, and adverse effects of  MSCs 
are needed to determine if  their immunomodulatory 
properties will evolve from theoretical interest to clini-
cal benefit.
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